We are Stibbe Life Sciences specialists

In an increasingly complex legal environment, we deliver workable and pragmatic solutions that cater to all our clients’ needs.

Life Sciences

We have one the largest IP and life sciences teams in the Benelux with decades of expertise and experience in related areas of law.

We provide a full range of services to companies active in the pharmaceutical, biotechnological, medical device and food sectors. Our activity encompasses both EU and domestic regulations creating practical solutions that work in the short and long term interests of our clients.

We are active in numerous areas such as intellectual property (patents, trademarks, know-how), pricing/reimbursement, parallel imports, clinical trails, distribution, product registration including biosimilars, licences, R&D agreements and advertising. Furthermore, we have a strong litigation practice.

Our regular contact with public authorities and institutions such as the European Commission, the European Medicines Agency and all Benelux medicines agencies, works to benefit our clients’ position and legal strategy. 

We also regularly team with colleagues who specialise in administrative law and EU/competition law to provide coordinated, integrated solutions for our clients.

Subscribe to newsletter

Experience

Market recognition

Stibbe’s ‘excellent’ and ‘responsive’ team has detailed knowledge encompassing all aspects of IP law.

Legal 500 2014, Intellectual Property chapter

Stibbe acts for high-profile clients in the healthcare and life sciences sector, with a focus on intellectual property law and regulatory work

Legal 500 2015, Health and Life sciences chapter

Other specialists

Related news

22.09.2016 NL law
Tax alert: Dutch Government presents the 2017 budget

Trends - On 20 September 2016, the Dutch government presented the 2017 Budget. As part thereof legislative proposals were submitted to Dutch Parliament on the amendment of certain tax laws in the Netherlands. Below, we will summarize some of the rules which are relevant for internationally oriented corporate taxpayers, that will apply as from 1 January 2017. Please note that the summary is based on the current version of the legislative proposal which is still subject to parliamentary approval.

Read more

11.08.2017 BE law
Juridisch kader voor pesticidengebruik en voedselveiligheid: fipronil voor dummies

Articles - Elke producent die pesticiden met actieve bestanddelen, zoals fipronil, op de Europese markt wil brengen, is afhankelijk van een Europese en nationale toelating. Die toelating is slechts tijdelijk. Daarenboven moeten de residuen van bepaalde stoffen (zoals fipronil) in ons voedsel onder een maximumgrens blijven. Hierna geven wij u een basisinzicht hoe pesticiden op de Belgische – en bij uitbreiding de Europese – markt kunnen terechtkomen. Als voorbeeld nemen we, hoe kan het anders, de stof fipronil.

Read more

25.10.2016 EU law
A cautionary tale - EU merger control rules may apply to pharma pipeline products

Articles - In Case M.7872 – Novartis/GlaxoSmithKline (ofatumumab autoimmune indications), the European Commission claimed jurisdiction under the merger control rules over a transaction by virtue of which a yet to be fully developed biological drug was transferred to a purchaser. In applying the relevant jurisdictional test, the Commission made a series of observations which have far-reaching implications. 

Read more

04.07.2016 BE law
The impact of Brexit on the pharmaceutical industry

Trends - Following the Brexit referendum, the UK should, in principle, notify its decision in the coming months to withdraw from the EU as provided by Article 50 of the Treaty on the European Union. According to Article 50, the Treaties will cease to apply to the UK from the date of entry into force of the withdrawal agreement or, failing that, two years after the notification—unless the European Council, in agreement with the UK, decides to extend this period unanimously.

Read more

27.06.2016 BE law
The International Comparative Legal Guide to: Pharmaceutical Advertising 2016 – Belgium Chapter

Articles - ICLG’s International Comparative Legal Guide to: Pharmaceutical Advertising 2016 provides corporate counsel and international practitioners with a comprehensive worldwide legal analysis of pharmaceutical advertising laws and regulations, including advertisements to healthcare professionals, gifts and financial incentives, and so on.

Read more

Our website uses cookies: third party analytics cookies to best adapt our website to your needs & cookies to enable social media functionalities. For more information on the use of cookies, please check our Privacy and Cookie Policy. Please note that you can change your cookie opt-ins at any time via your browser settings.

Privacy and Cookie Policy